WASHINGTON (dpa-AFX) - Inovio (INO) said that the European Commission granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory Papillomatosis
Inovio Pharma (INO) Granted FDA Orphan Drug Designation for INO-3107 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related. | May 23, 2023
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the.
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and